A phase I study of PT-112 in advanced solid tumors.

被引：3
|
作者：
Karp, Daniel D.
Camidge, D. Ross
Bryce, Alan Haruo
Jimeno, Jose
Infante, Jeffrey R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase I Program, Houston, TX 77030 USA
[2] Univ Colorado Denver, Aurora, CO USA
[3] Mayo Clin, Phoenix, AZ USA
[4] Pangaea Biotech SL, Barcelona, Spain
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Tennessee Oncol PLLC, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2519
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2519
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours
    Karp, Daniel D.
    Camidge, D. Ross
    Infante, Jeffery R.
    Ames, Tyler D.
    Price, Matthew R.
    Jimeno, Jose
    Bryce, Alan H.
    ECLINICALMEDICINE, 2022, 49
  • [2] Phase I study of regorafenib and sildenafil in advanced solid tumors.
    Poklepovic, Andrew Stewart
    Gordon, Sarah W.
    McGuire, William P.
    Thacker, Leroy R.
    Deng, Xiaoyan
    Tombes, Mary Beth
    Shrader, Ellen
    Ryan, Alison A.
    Kmieciak, Maciej
    Dent, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Phase I study of pemetrexed and sorafenib in advanced solid tumors.
    Poklepovic, Andrew Stewart
    Shafer, Danielle A.
    Roberts, John D.
    Geyer, Charles E.
    Dent, Paul
    Moran, Richard
    Tombes, Mary Beth
    Shrader, Ellen
    Strickler, Kathryn
    Wan, Wen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors.
    Sandler, Alan
    Taylor, Matthew Hiram
    Urba, Walter John
    Omuro, Antonio Marcilio Padula
    Anderson, Barry Douglas
    Hansen, Daniel
    Fisher, Brenda
    Claeys, Alisa J.
    Greathouse, Amy
    McLean, Sean
    Karmali, Rashida A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.
    Tolaney, Sara M.
    Hilton, John Frederick
    Cleary, James M.
    Gandhi, Leena
    Kwak, Eunice Lee
    Clark, Jeffrey W.
    Wolanski, Andrew
    Bell, Tracy Demeo
    Rodig, Scott J.
    Chiao, Judy H.
    Blake, David
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] A phase I QTc study of tivozanib in patients with advanced solid tumors.
    Chadha, Manpreet Kaur
    Infante, Jeffrey R.
    Cotreau, Monette M.
    Jacobson, Lindsey
    Strahs, Andrew Louis
    Slichenmyer, William
    Vargo, Dennis
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [7] Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors.
    Jones, S. F.
    Plummer, E. R.
    Burris, H. A.
    Razak, A. R.
    Meluch, A. A.
    Bowen, C. J.
    Williams, D. H.
    Hodge, J. P.
    Dar, M. M.
    Calvert, A. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 85S - 85S
  • [8] Phase I study of weekly docetaxel and topotecan in the treatment of advanced solid tumors.
    Tan, BR
    Read, W
    Bergeron, K
    Fracasso, PM
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 702S - 702S
  • [9] Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors.
    Hollebecque, Antoine
    Bahleda, Rastislav
    Thery, Jean Christophe
    Faivre, Laura
    Le Deley, Marie-Cecile
    Paci, Angelo
    Varga, Andrea
    Gazzah, Anas
    Massard, Christophe
    Poinsignon, Vianney
    Malekzadeh, Katty
    Ribrag, Vincent
    Angevin, Eric
    Postel-Vinay, Sophie
    Gomez-Roca, Carlos Alberto
    Gharib, Myriam
    Dufour, Fabienne
    Soria, Jean-Charles
    Spano, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Phase I study of MEDI0639 in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Dowlati, Afshin
    Naing, Aung
    Gribbin, Matthew Joseph
    Jenkins, David William
    Chang, Linda L.
    Lai, Dominic W.
    Smith, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345